CoChat
Sign Up
Cited by 23

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Has-miR-129-5p’s Involvement in Different Disorders, from Digestive Cancer to Neurodegenerative Diseases

Boicean, Adrian, Birsan, Sabrina, Ichim, Cristian, Boeras, Ioana, Roman-Filip, Iulian, Blanca, Grama, Bacila, Ciprian, Fleaca, Radu Sorin, Dura, Horatiu, Roman-Filip, Corina·2023·Biomedicines
DOI 10.3390/biomedicines11072058PMC PMC10377727
Open this paper in CoChat — free account

Abstract

At present, it is necessary to identify specific biochemical, molecular, and genetic markers that can reliably aid in screening digestive cancer and correlate with the degree of disease development. Has-miR-129-5p is a small, non-coding molecule of RNA, circulating in plasma, gastric juice, and other biological fluids; it plays a protective role in tumoral growth, metastasis, etc. Furthermore, it is involved in various diseases, from the development of digestive cancer in cases of downregulation to neurodegenerative diseases and depression. Methods: We examined meta-analyses, research, and studies related to miR-129-5-p involved in digestive cancer and its implications in cancer processes, as well as metastasis, and described its implications in neurological diseases. Conclusions: Our review outlines that miR-129-5p is a significant controller of different pathways, genes, and proteins and influences different diseases. Some important pathways include the WNT and PI3K/AKT/mTOR pathways; their dysregulation results in digestive neoplasia and neurodegenerative diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/biomedicines11072058

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Research strategy.
Figure 1 Research strategy.CC BY · PubMed Central
Figure 2 Protective role of miR-129-5p in preventing tumoral progression in different types of cancer. Overstimulation of miR129 targets WNT signaling pathway resulting in decreasing hepatoma-derived growth factor (HDGF) and HCC risk. Upregulation of miR-129-5p decreases COL1A1, ADAM 9 protein, and HMGB protein, lowering gastric cancer risk and decreasing IPO7 protein, resulting in suppressing pancreatic cancer proliferation.
Figure 2 Protective role of miR-129-5p in preventing tumoral progression in different types of cancer. Overstimulation of miR129 targets WNT signaling pathway resulting in decreasing hepatoma-derived growth factor (HDGF) and HCC risk. Upregulation of miR-129-5p decreases COL1A1, ADAM 9 protein, and HMGB protein, lowering gastric cancer risk and decreasing IPO7 protein, resulting in suppressing pancreatic cancer proliferation.CC BY · PubMed Central
Figure 3 Overstimulation of MiR-129-5p plays a protective role in reducing neural inflammation and preventing Alzheimer’s disease (AD) by reducing the expression of the SOX6 gene. Controlling the signaling pathway PI3K/AKT/mTOR represents a possible treatment in AD and PD. Upregulation of miR-129-5p targets genes and maintains neuronal homeostasis. Also, by lowering the activity of the mutant FMR1 gene, miR-129-5p reduces the risk for diseases in the autism spectrum and Fragile X Syndrome.
Figure 3 Overstimulation of MiR-129-5p plays a protective role in reducing neural inflammation and preventing Alzheimer’s disease (AD) by reducing the expression of the SOX6 gene. Controlling the signaling pathway PI3K/AKT/mTOR represents a possible treatment in AD and PD. Upregulation of miR-129-5p targets genes and maintains neuronal homeostasis. Also, by lowering the activity of the mutant FMR1 gene, miR-129-5p reduces the risk for diseases in the autism spectrum and Fragile X Syndrome.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 56

  1. Xu, 2021, Pancreatic Cancer Progression Is Regulated by IPO7/p53/LncRNA MALAT1/MiR-129-5p Positive Feedback Loop, Front. Cell Dev. Biol., 9, 630262, 10.3389/fcell.2021.630262 · DOI
  2. Qiu, 2019, miR-129-5p suppresses proliferation, migration, and induces apoptosis in pancreatic cancer cells by targeting PBX3, Acta Biochim. Biophys. Sin., 51, 997, 10.1093/abbs/gmz096 · DOI
  3. Kipkeeva, F., Muzaffarova, T., Korotaeva, A., Nikulin, M., Grishina, K., Mansorunov, D., Apanovich, P., and Karpukhin, A. (2020). MicroRNA in Gastric Cancer Development: Mechanisms and Biomarkers. Diagnostics, 10. · DOI
  4. Long, 2021, PI3K/AKT Signal Pathway: A Target of Natural Products in the Prevention and Treatment of Alzheimer’s Disease and Parkinson’s Disease, Front Pharmacol., 12, 648636, 10.3389/fphar.2021.648636 · DOI
  5. Zhao, 2019, Research progress in microRNA-based therapy for gastric cancer, OncoTargets Ther., 12, 11393, 10.2147/OTT.S221354 · DOI
  6. Herrera-Pariente, C., Montori, S., Llach, J., Bofill, A., Albeniz, E., and Moreira, L. (2021). Biomarkers for Gastric Cancer Screening and Early Diagnosis. Biomedicines, 9. · DOI
  7. 2020, The Promising Role of miR-21 as a Cancer Biomarker and Its Importance in RNA-Based Therapeutics, Mol. Ther. Nucleic Acids, 20, 409, 10.1016/j.omtn.2020.03.003 · DOI · Paper page
  8. Jiang, 2016, MiR-129-5p is down-regulated and involved in migration and invasion of gastric cancer cells by targeting interleukin-8, Neoplasma, 63, 673, 10.4149/neo_2016_503 · DOI
  9. Chen, 2021, LncRNA PCGEM1 mediates oxaliplatin resistance in hepatocellular carcinoma via miR-129-5p/ETV1 axis in vitro, Adv. Clin. Exp. Med., 30, 831, 10.17219/acem/135533 · DOI
  10. Huge, 2022, MiR-129-5p exerts Wnt signaling-dependent tumor-suppressive functions in hepatocellular carcinoma by directly targeting hepatoma-derived growth factor HDGF, Cancer Cell Int., 22, 1, 10.1186/s12935-022-02582-2 · DOI
  11. Wang, 2018, MiR-129-5p suppresses gastric cancer cell invasion and proliferation by inhibiting COL1A1, Biochem. Cell Biol., 96, 19, 10.1139/bcb-2016-0254 · DOI
  12. Serafino, 2020, Targeting the Wnt/β-catenin pathway in neurodegenerative diseases: Recent approaches and current challenges, Expert Opin. Drug Discov., 15, 803, 10.1080/17460441.2020.1746266 · DOI
  13. Wan, 2020, miR-129-5p inhibits proliferation, migration, and invasion in rectal adenocarcinoma cells through targeting E2F7, J. Cell. Physiol., 235, 5689, 10.1002/jcp.29501 · DOI
  14. Ho, 2023, Single cell quantification of microRNA from small numbers of non-invasively sampled primary human cells, Commun. Biol., 6, 458, 10.1038/s42003-023-04845-8 · DOI
  15. Chiurillo, 2015, Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review, World J. Exp. Med., 5, 84, 10.5493/wjem.v5.i2.84 · DOI
  16. Yan, 2017, MiR-129-5p influences the progression of gastric cancer cells through interacting with SPOCK1, Tumor Biol., 39, 1010428317706916, 10.1177/1010428317706916 · DOI
  17. Kalita, 2023, Role of Some microRNA/ADAM Proteins Axes in Gastrointestinal Cancers as a Novel Biomarkers and Potential Therapeutic Targets—A Review, Curr. Issues Mol. Biol., 45, 2917, 10.3390/cimb45040191 · DOI
  18. Chandrasekera, 2022, Metalloprotease ADAM9 cleaves ephrin-B ligands and differentially regulates Wnt and mTOR signaling downstream of Akt kinase in colorectal cancer cells, J. Biol. Chem., 298, 102225, 10.1016/j.jbc.2022.102225 · DOI
  19. Grutzmann, 2004, ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma, Br. J. Cancer, 90, 1053, 10.1038/sj.bjc.6601645 · DOI
  20. Oh, S., Park, Y., Lee, H.-J., Lee, J., Lee, S.-H., Baek, Y.-S., Chun, S.-K., Lee, S.-M., Kim, M., and Chon, Y.-E. (2020). A Disintegrin and Metalloproteinase 9 (ADAM9) in Advanced Hepatocellular Carcinoma and Their Role as a Biomarker During Hepatocellular Carcinoma Immunotherapy. Cancers, 12. · DOI
  21. Feng, 2020, MiR-129-5p inhibits proliferation of gastric cancer cells through targeted inhibition on HMGB1 expression, Eur. Rev. Med. Pharmacol. Sci., 24, 3665
  22. Kaya, 2014, The role of high mobility group box 1 (HMGB1) in colorectal cancer, Med. Sci. Monit., 20, 530, 10.12659/MSM.890531 · DOI
  23. Chen, 2018, High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis, Hepatology, 67, 1823, 10.1002/hep.29663 · DOI
  24. Kang, 2018, The Dual Role of HMGB1 in Pancreatic, Cancer J. Pancreatol., 1, 19, 10.1097/JP9.0000000000000002 · DOI
  25. Stelow, 2010, Pancreatic Acinar Cell Carcinomas with Prominent Ductal Differentiation: Mixed Acinar Ductal Carcinoma and Mixed Acinar Endocrine Ductal Carcinoma, Am. J. Surg. Pathol., 34, 510, 10.1097/PAS.0b013e3181cfcac7 · DOI
  26. Hosoda, 2016, Molecular Genetics of Pancreatic Neoplasms, Surg. Pathol. Clin., 9, 685, 10.1016/j.path.2016.05.011 · DOI
  27. Karaayvaz, 2013, miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer, Cell Death Dis., 4, e659, 10.1038/cddis.2013.193 · DOI
  28. Yin, 2012, MicroRNAs as Diagnostic Biomarkers in Gastric Cancer, Int. J. Mol. Sci., 13, 12544, 10.3390/ijms131012544 · DOI
  29. Serafino, 2017, Developing drugs that target the Wnt pathway: Recent approaches in cancer and neurodegenerative diseases, Expert Opin. Drug Discov., 12, 169, 10.1080/17460441.2017.1271321 · DOI
  30. Zeng, 2019, MicroRNA-129-5p alleviates nerve injury and inflammatory response of Alzheimer’s disease via downregulating SOX6, Cell Cycle, 18, 3095, 10.1080/15384101.2019.1669388 · DOI
  31. Geng, 2016, MiR-129-5p-mediated Beclin-1 suppression inhibits endothelial cell autophagy in atherosclerosis, Am. J. Transl. Res., 8, 1886
  32. Chen, 2019, Relationship between long non-coding RNAs and Alzheimer’s disease: A systematic review, Pathol. Res. Pract., 215, 12, 10.1016/j.prp.2018.11.012 · DOI
  33. Li, 2021, Insights into lncRNAs in Alzheimer’s disease mechanisms, RNA Biol., 18, 1037, 10.1080/15476286.2020.1788848 · DOI
  34. Jiang, 2022, Non-coding RNAs: The Neuroinflammatory Regulators in Neurodegenerative Diseases, Front. Neurol., 13, 929290, 10.3389/fneur.2022.929290 · DOI
  35. Chen, 2021, Long non-coding RNA: An underlying bridge linking neuroinflammation and central nervous system diseases, Neurochem. Int., 148, 105101, 10.1016/j.neuint.2021.105101 · DOI
  36. Li, 2017, Upregulation of miR-202-5p promotes cell apoptosis and suppresses cell viability of hypoxia-induced myocardial H9c2 cells by targeting SOX6 to inhibit the activation of the PI3K/AKT/FOXO3a pathway, Int. J. Clin. Exp. Pathol., 10, 8884
  37. Iranpanah, A., Kooshki, L., Moradi, S.Z., Saso, L., Fakhri, S., and Khan, H. (2023). The Exosome-Mediated PI3K/Akt/mTOR Signaling Pathway in Neurological Diseases. Pharmaceutics, 15. · DOI
  38. Mattson, 2004, Pathways towards and away from Alzheimer’s disease, Nature, 430, 631, 10.1038/nature02621 · DOI · Paper page
  39. Dobricic, 2022, Common signatures of differential microRNA expression in Parkinson’s and Alzheimer’s disease brains, Brain Commun., 4, fcac274, 10.1093/braincomms/fcac274 · DOI · Paper page
  40. Loffreda, 2020, miR-129-5p: A key factor and therapeutic target in amyotrophic lateral sclerosis, Prog. Neurobiol., 190, 101803, 10.1016/j.pneurobio.2020.101803 · DOI
  41. Li, 2018, MicroRNA-132 provides neuroprotection for tauopathies via multiple signaling pathways, Acta Neuropathol., 136, 537, 10.1007/s00401-018-1880-5 · DOI · Paper page
  42. Kuo, 2021, The role of noncoding RNAs in Parkinson’s disease: Biomarkers and associations with pathogenic pathways, J. Biomed. Sci., 28, 78, 10.1186/s12929-021-00775-x · DOI
  43. Chen, 2018, MicroRNA-129-5p Regulates Glycolysis and Cell Proliferation by Targeting the Glucose Transporter SLC2A3 in Gastric Cancer Cells, Front. Pharmacol., 9, 502, 10.3389/fphar.2018.00502 · DOI
  44. Improta-Caria, A.C., Nonaka, C.K.V., Cavalcante, B.R.R., De Sousa, R.A.L., Júnior, R.A., and Souza, B.S.D.F. (2020). Modulation of MicroRNAs as a Potential Molecular Mechanism Involved in the Beneficial Actions of Physical Exercise in Alzheimer Disease. Int. J. Mol. Sci., 21. · DOI
  45. Wu, 2019, MicroRNA-129 modulates neuronal migration by targeting Fmr1 in the developing mouse cortex, Cell Death Dis., 10, 287, 10.1038/s41419-019-1517-1 · DOI
  46. Zongaro, 2013, The 3′ UTR of FMR1 mRNA is a target of miR-101, miR-129-5p and miR-221: Implications for the molecular pathology of FXTAS at the synapse, Hum. Mol. Genet., 22, 1971, 10.1093/hmg/ddt044 · DOI
  47. Rajman, 2017, A microRNA-129-5p/Rbfox crosstalk coordinates homeostatic downscaling of excitatory synapses, EMBO J., 36, 1770, 10.15252/embj.201695748 · DOI · Paper page
  48. Deng, 2021, Role of microRNA-129 in cancer and non-cancerous diseases (Review), Exp. Ther. Med., 22, 918, 10.3892/etm.2021.10350 · DOI
  49. Ishaq, Y., Ikram, A., Alzahrani, B., and Khurshid, S. (2023). The Role of miRNAs, circRNAs and Their Interactions in Development and Progression of Hepatocellular Carcinoma: An Insilico Approach. Genes, 14. · DOI
  50. Yao, 2021, MicroRNA-129 plays a protective role in sepsis-induced acute lung injury through the suppression of pulmonary inflammation via the modulation of the TAK1/NF-κB pathway, Int. J. Mol. Med., 48, 139, 10.3892/ijmm.2021.4972 · DOI
  51. Qinlin, 2022, miR-129-5p targets FEZ1/SCOC/ULK1/NBR1 complex to restore neuronal function in mice with post-stroke depression, Bioengineered, 13, 9708, 10.1080/21655979.2022.2059910 · DOI
  52. Lourenco, 2013, TNF-α mediates PKR-dependent memory impairment and brain IRS-1 inhibition induced by Alzheimer’s β-amyloid oligomers in mice and monkeys, Cell Metab., 18, 831, 10.1016/j.cmet.2013.11.002 · DOI
  53. Xu, 2020, Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours, Cell Biosci., 10, 54, 10.1186/s13578-020-00416-0 · DOI
  54. Vadlakonda, 2013, Role of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells, Front Oncol., 12, 85
  55. Balaskas, P., Goljanek-Whysall, K., Clegg, P.D., Fang, Y., Cremers, A., Smagul, A., Welting, T.J.M., and Peffers, M.J. (2023). MicroRNA Signatures in Cartilage Ageing and Osteoarthritis. Biomedicines, 11. · DOI
  56. Wang, I.-F., Ho, P.-C., and Tsai, K.-J. (2022). MicroRNAs in Learning and Memory and Their Impact on Alzheimer’s Disease. Biomedicines, 10. · DOI

Cited by

Sorted by citations

See all 23

Metadata

Authors
Boicean, A., Birsan, S., Ichim, C., Boeras, I., Roman-Filip, I., Blanca, G., Bacila, C., Fleaca, R. S., Dura, H., & Roman-Filip, C.
Affiliations
  • Faculty of Medicine, Lucian Blaga University of Sibiu, 550169 Sibiu, Romania
  • Molecular Biology Laboratory of the Applied Ecology Research Center, Faculty of Sciences, Lucian Blaga University of Sibiu, 550012 Sibiu, Romania
  • Department of Neurology, “George Emil Palade” University of Medicine, Pharmacy, Sciences and Technology, 540136 Targu Mures, Romania
  • Faculty of Social Sciences, Lucian Blaga University of Sibiu, 550012 Sibiu, Romania
ORCID
Venue
Biomedicines
Publisher
MDPI AG
Published
2023-07-21
Volume
11
Issue
7
Pages
2058
ISSN
2227-9059
DOI
10.3390/biomedicines11072058
PMC
PMC10377727
Cited by
23
References
3
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • Ministry of Research, Innovation, and Digitization (28PFE/30.12.2021)
  • Lucian Blaga University of Sibiu (28PFE/30.12.2021)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review